<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="81769">
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on April 10, 2017</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02040844</url>
  </required_header>
  <id_info>
    <org_study_id>CP007 A</org_study_id>
    <nct_id>NCT02040844</nct_id>
  </id_info>
  <brief_title>Phase III Cat-PAD Follow-on Study</brief_title>
  <official_title>An Optional Prospective Follow-on Study to Evaluate the Continued Efficacy and Safety of Cat-PAD in Cat Allergic Subjects up to Five Years After the Administration of Treatment</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Circassia Limited</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Circassia Limited</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to evaluate the continued effectiveness and safety of Cat-PAD
      in cat allergic subjects for up to five years after the start of administration of
      treatment. The study is an optional follow-up study to a phase III double-blind, placebo
      controlled, Cat-PAD study; no further investigational product is administered.
    </textblock>
  </brief_summary>
  <overall_status>Enrolling by invitation</overall_status>
  <start_date>February 2014</start_date>
  <primary_completion_date type="Anticipated">May 2019</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Other</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Combined Score of symptoms and allergy medication</measure>
    <time_frame>1, 2, 3 and 4 years</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Symptom scores</measure>
    <time_frame>1, 2, 3 and 4 years</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Allergy Medication use</measure>
    <time_frame>1, 2, 3 and 4 years</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Quality of Life</measure>
    <time_frame>1, 2, 3 and 4 years</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Concomitant medication use</measure>
    <time_frame>up to 5 years</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Adverse Events</measure>
    <time_frame>up to 5 years</time_frame>
  </secondary_outcome>
  <number_of_groups>3</number_of_groups>
  <enrollment type="Anticipated">1182</enrollment>
  <condition>Cat Allergy</condition>
  <arm_group>
    <arm_group_label>Cat-PAD Treatment 1</arm_group_label>
    <description>Received Cat-PAD Treatment 1 in Study CP007 [NCT01620762]</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Cat-PAD Treatment 2</arm_group_label>
    <description>Received Cat-PAD Treatment 2 in Study CP007 [NCT01620762]</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Cat-PAD Treatment 3</arm_group_label>
    <description>Received Cat-PAD Treatment 3 in Study CP007 [NCT01620762]</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Received Cat-PAD Treatment 1 in Study CP007 [NCT01620762]</intervention_name>
    <arm_group_label>Cat-PAD Treatment 1</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Received Cat-PAD Treatment 2 in Study CP007 [NCT01620762]</intervention_name>
    <arm_group_label>Cat-PAD Treatment 2</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Received Cat-PAD Treatment 3 in Study CP007 [NCT01620762]</intervention_name>
    <arm_group_label>Cat-PAD Treatment 3</arm_group_label>
  </intervention>
  <eligibility>
    <study_pop>
      <textblock>
        Subjects who have previously completed clinical study CP007 [NCT01620762]
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  previously completed clinical study CP007 [NCT01620762]

        Exclusion Criteria:

          -  started allergen therapy since completing CP007

          -  Institutionalised due to a legal or regulatory order
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>N/A</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>JÃ¶rg Kleine-Tebbe, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Clinical Research Center for Dermatology, Allergy &amp; Asthma</affiliation>
  </overall_official>
  <verification_date>January 2017</verification_date>
  <lastchanged_date>January 30, 2017</lastchanged_date>
  <firstreceived_date>January 17, 2014</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
